Exploring microbial metabolites in kidney disease: insights into molecular pathways and novel metabolite-targeted therapeutic approaches
Year: 2026
Type: article
Abstract: Chronic kidney disease (CKD) is increasingly recognised as a systemic disorder in which a bidirectional host–microbiota relationship contributes to disease progression. This review is deliberately restricted in scope to the microbial metabolites for which mechanistic and clinical evidence is most developed: the protein-bound uremic solutes indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), and the microbiota-derived co-metabolite trimethylamine N-oxide (TMAO). These harmful metabolites are explicitly contrasted with short-chain fatty acids (SCFAs), the principal class of beneficial microbial metabolites, whose depletion represents a loss of reno-protection rather than a gain of toxicity. In CKD, the colonic milieu is reshaped by urea influx, restricted fruit, vegetable and fibre intake, slowed intestinal transit and repeated antibiotic and phosphate-binder exposure; the resulting dysbiosis favours proteolytic fermentation and the generation of indole and p-cresol, which undergo hepatic and intestinal phase II conjugation to IS and p-CS, while choline- and carnitine-derived trimethylamine is oxidised by hepatic flavin monooxygenase 3 to TMAO. Because these solutes are highly protein-bound, they are poorly cleared by conventional haemodialysis and accumulate as renal function declines. At the molecular level, IS is a well-characterised (AhR), and AhR activation, NADPH-oxidase-derived reactive oxygen species, NF-κB-dependent cytokine transcription and TGF-β1/Smad3-driven matrix deposition together form the best-supported injury cascade; other links, notably metabolite-directed epigenetic remodelling, remain hypothesis-generating. Therapeutic strategies are appraised according to their development stage and the strength of the evidence behind them, from the oral adsorbent AST-120 - whose pivotal EPPIC trials did not meet their primary endpoint - through investigational microbial enzyme inhibitors to experimental AhR antagonists. We argue that the field’s central unmet need is not further descriptive mechanistic work but biomarker-enriched, adequately powered and earlier-initiated clinical trials capable of distinguishing metabolite lowering from clinical benefit.
Source: Frontiers in Pharmacology
Authors: Jindong Dai(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft), Xiaohua Tang(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft), Sathyamoorthi S(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft), Yuerong Zou(Investigation, Methodology, Software, Writing – original draft), Kanagaraj Rajalakshmi(Formal analysis, Methodology, Software, Writing – original draft), Vijayakumar Murugesan(Investigation, Methodology, Software, Writing – review & editing), Selvaraj Muthusamy(Formal analysis, Investigation, Methodology, Writing – review & editing), Panneerselvam Theivendren(Formal analysis, Investigation, Methodology, Writing – review & editing), Dongwei Zhu(Conceptualization, Funding acquisition, Project administration, Supervision, Validation, Visualization, Writing – review & editing)
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: chronic kidney disease, microbial metabolites, uremic solutes, indoxyl sulfate, p-cresyl sulfate, trimethylamine N-oxide, gut microbiota, short-chain fatty acids, dysbiosis, protein-bound solutes, aryl hydrocarbon receptor, reactive oxygen species, NF-κB, epigenetic remodeling, AST-120, AhR antagonists, biomarkers
Open Access status: gold
Estimated APC paid: $3,801
Award: G666264997
OpenAlex ID: W7235722530
